Articles

Latest Comings and Goings in Pharma Leadership

This article covers recent leadership transitions in the pharmaceutical sector, highlighting their potential impacts on business strategies and market dynamics.

Marty Makary's Misunderstanding of the FDA: An Analysis

This article analyzes Marty Makary's opinions on the FDA, highlighting key misunderstandings and their implications for the pharmaceutical sector.

Takeda Settles Kickback Allegations: What It Means for Pharma

Takeda has agreed to a $13.6 million settlement regarding allegations of kickbacks to doctors. This article explores the implications for the pharmaceutical sector.

Global Preparedness: Lessons from Hantavirus and Ebola Outbreaks

This article examines the implications of recent hantavirus and Ebola outbreaks on global health preparedness and the pharmaceutical sector.

U.S. Pressure on Germany: Implications for Pharma and Biotech

This article examines the U.S. pressure on Germany over drug prices, the upheaval within the FDA, and the current state of biotech clinical trials, providing insights for analysts and business development teams.

New Ebola Outbreak in Congo: Implications for Pharma

A new Ebola outbreak has been confirmed in a remote province of Congo, resulting in 65 deaths. This article explores the implications for pharmaceutical companies.

M&A Trends: Mid-Size Pharma Companies on the Rise

Mid-size pharmaceutical companies are stepping up their M&A activities, challenging the dominance of big pharma. This article explores the implications for business development teams and investors.

Post-Hoc Live: Makary's Departure from FDA and Future Implications

This article examines the recent departure of Makary from the FDA and its potential impact on the pharmaceutical landscape.

Amgen's Expanded Crackdown on 340B Program Misuse

Amgen has intensified its efforts to address what it claims is the misuse of the 340B program. This article explores the implications for the pharmaceutical sector.

UK Political Contest Could Impact Drug Pricing: Insights for Pharma

A political contest in the UK could significantly alter drug pricing dynamics. This article explores the implications for pharmaceutical businesses.

CDER Leadership Changes: Implications for Pharma

The potential departure of CDER chief Tracy Beth Høeg raises questions about the future of FDA leadership and its impact on the pharma sector.

Supreme Court Ruling on Mifepristone: Implications for Pharma

The Supreme Court's decision to preserve access to mifepristone by mail has significant implications for the pharmaceutical sector, particularly in abortion care.

Aardvark's Next Move After Clinical Hold: Alumis' Verdict on Acelyrin

This article explores Aardvark's strategic decisions following a clinical hold and Alumis' evaluation of the Acelyrin asset, highlighting implications for the pharmaceutical industry.

#ASGCT26: Zillow-like Marketplace for Abandoned Gene Therapies

A new marketplace for abandoned gene therapies has launched, drawing parallels to Zillow. This article explores its implications for the pharmaceutical industry.

Makary Resigns; Biogen Reports Alzheimer’s Data: Key Insights

This article discusses the recent resignation of Makary and Biogen's latest Alzheimer’s data, highlighting their implications for the pharmaceutical sector.

STAT+: Up and Down the Ladder - Latest Comings and Goings

This article delves into the recent comings and goings within the pharmaceutical sector, highlighting key personnel changes and their potential impacts on the industry landscape.

Biopharma M&A Strength Amidst Declining Large Deals

Despite a decline in large biopharma mergers and acquisitions, the sector remains robust. This article explores the implications for business development teams and investors.

Trump Criticizes Sen. Cassidy Amid Louisiana Republican Primary

In a recent political development, Trump criticized Sen. Cassidy as he endorses a challenger in the Louisiana Republican primary, raising questions for pharma stakeholders.

U.S. Pressure on Germany's Drug Prices: Implications for Pharma

This article delves into the U.S. government's pressure on Germany to lower drug prices, the FDA's recent upheaval, and the status of biotech clinical trials.

Eisai's Leqembi Sales Forecast: A Closer Look at $900M Potential

Eisai is making strides toward achieving blockbuster status for Leqembi, with a projected sales forecast of $900M. This article explores the implications for the pharmaceutical landscape.